Education
About Us
Working with TipRanks
Follow Us
Novartis Ag (NVS)
NYSE:NVS
NVS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$96.06 - $128.03
Previous CloseN/A
Volume597.99K
Average Volume (3M)1.82M
Market Cap
$239.54B
Enterprise Value$262.89B
Total Cash (Recent Filing)$7.00B
Total Debt (Recent Filing)$32.64B
Price to Earnings (P/E)18.3
Beta0.34
Next Earnings
Oct 28, 2025EPS Estimate
2.25Last Dividend Ex-Date
Mar 12, 2025Dividend Yield3.15%
Share Statistics
EPS (TTM)2.42
Shares Outstanding2,112,421,900
10 Day Avg. Volume1,286,550
30 Day Avg. Volume1,818,898
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue4.81
Enterprise Value/Gross Profit8.60
Enterprise Value/Ebitda15.80
Forecast
1Y Price Target
$115.50Price Target Upside-8.98% Downside
Rating ConsensusHold
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Financial PerformanceIncreased cash on the balance sheet has led to a modestly higher target price for Novartis.
Product DevelopmentCosentyx is maintaining its NBRx share despite increased competition and is expected to grow further with the approval of the HS indication and IV formulation.
Trial ResultsKisqali's NATALEE trial results have received positive feedback from physicians, indicating excitement for its use among eBC patients.
Bears Say
Revenue ExpectationsThe target price implies modest upside from current levels, suggesting that revenue upside is mostly priced in.
Novartis News
NVS FAQ
What was Novartis Ag’s price range in the past 12 months?
Novartis Ag lowest stock price was $96.06 and its highest was $128.03 in the past 12 months.
What is Novartis Ag’s market cap?
Novartis Ag’s market cap is $239.54B.
When is Novartis Ag’s upcoming earnings report date?
Novartis Ag’s upcoming earnings report date is Oct 28, 2025 which is in 61 days.
How were Novartis Ag’s earnings last quarter?
Novartis Ag released its earnings results on Jul 17, 2025. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.351 by $0.069.
Is Novartis Ag overvalued?
According to Wall Street analysts Novartis Ag’s price is currently Overvalued.
Does Novartis Ag pay dividends?
Novartis Ag pays a Annually dividend of $3.994 which represents an annual dividend yield of 3.15%. See more information on Novartis Ag dividends here
What is Novartis Ag’s EPS estimate?
Novartis Ag’s EPS estimate is 2.25.
How many shares outstanding does Novartis Ag have?
Novartis Ag has 2,112,421,900 shares outstanding.
What happened to Novartis Ag’s price movement after its last earnings report?
Novartis Ag reported an EPS of $2.42 in its last earnings report, beating expectations of $2.351. Following the earnings report the stock price went down -3.253%.
Which hedge fund is a major shareholder of Novartis Ag?
Currently, no hedge funds are holding shares in NVS
Novartis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$115.50 (-8.98% Downside)
$115.50 (-8.98% Downside)
Blogger Sentiment
Bullish
NVS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 869.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days >0.1%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.50%
12-Months-Change
Fundamentals
Return on Equity
32.82%
Trailing 12-Months
Asset Growth
7.07%
Trailing 12-Months
Company Description
Novartis Ag
Novartis AG is a global healthcare company based in Switzerland, focused on the research, development, manufacturing, and marketing of innovative pharmaceuticals and generics. The company operates through two main business segments: Innovative Medicines, which includes patented drugs primarily aimed at treating diseases in areas such as oncology, cardiology, immunology, and neuroscience, and Sandoz, which specializes in generic pharmaceuticals and biosimilars. Novartis is committed to addressing the evolving needs of patients worldwide through its extensive portfolio of medications and therapies.
NVS Company Deck
NVS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook for Novartis, with strong sales and income growth driven by key products like Kisqali, Kesimpta, and Pluvicto. The initiation of a new share buyback program further underscores confidence in future performance. However, challenges such as the slowing growth of Cosentyx and market slowdown in China present hurdles that the company will need to address.View all NVS earnings summariesNVS Stock 12 Month Forecast
Average Price Target
$115.50
▼(-8.98% Downside)
Technical Analysis
Ownership Overview
―
Insiders
1.76% Mutual Funds
2.51% Other Institutional Investors
95.45% Public Companies and Individual Investors